Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for the manufacturing of various types of gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery... see more

CSE:SONA - Post Discussion

Sona Nanotech Inc > From the New York Times - July 6th 2020
View:
Post by NorthBayStreet on Jul 07, 2020 10:31pm

From the New York Times - July 6th 2020

So far, only two companies have received emergency authorization from the F.D.A. for coronavirus antigen tests. One is Quidel, which is, according to a representative, producing millions of tests each month, many of which have been distributed to urgent care centers and medical clinics in the United States. On Monday, a second firm, Becton Dickinson & Company, also entered the fray with a point-of-care antigen test that can reportedly produce results in 15 minutes. While speedy, both Quidel’s and BD’s tests may produce false negatives between 15 and 20 percent of the time.

Other antigen tests have made headway overseas, and experts estimated that several more will likely seek clearance in the United States in coming months.

Comment by Cottrader on Jul 08, 2020 8:14am
not sure how either of them got fda approval; https://www.marketwatch.com/amp/story/fda-alerts-health-care-providers-about-false-positives-for-one-of-bds-covid-19-tests-2020-07-07
Comment by gonnasee on Jul 08, 2020 9:31am
The Americans want the testing to remain inhouse.  They wont spend money outside of the country.   Can anyone explain why Sona testing results at 96% only had 30 samples.  (way too small).   Something not right.  
Comment by bluebeard123 on Jul 08, 2020 9:35am
You can calculate sample size that gives enough statistical confidence in the results. It's all math.
Comment by NashDaSlash on Jul 08, 2020 9:39am
You don't know what you are talking about. Validation studies are set up by MRIGlobal, and SONA is continuing to bloster to their clinical data with in-field testing. Nothing sinister here. 
Comment by gonnasee on Jul 08, 2020 9:41am
Im just looking for clarification.  Below is from company news release.  To me this looks like they only tested 30 samples where other companies used 1000's Validation studies were also conducted in-house to assess potential clinical performance of the test using 30 nasopharyngeal samples from healthy individuals who were presumed negative for COVID-19. Results from the study ...more  
Comment by NashDaSlash on Jul 08, 2020 9:49am
Other companies used 1000s, why don't you list some links to these 3rd party validations using 1000s of samples?
Comment by bluebeard123 on Jul 08, 2020 9:50am
I know it sounds like a small sample size but minimum sample size to get a certain statistically confidence can be calculated. It's no different from polling.
Comment by Findingmoney on Jul 08, 2020 9:56am
This was part of the last NR, so they are doing tests within the USA, this is all speculation.  To that end, the Company has engaged with a contract research organization ("CRO") based in the U.S. to conduct one such study and a university-affiliated laboratory outside of the U.S. to conduct a second. The Company has been informed that the results of these field studies should be ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities